ATx09 002

Drug Profile

ATx09 002

Alternative Names: ATx09-002; PSN-357; PSN357AB

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Prosidion
  • Developer Aestus Therapeutics; Prosidion
  • Class Antihyperglycaemics
  • Mechanism of Action Glycogen phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Back pain
  • Preclinical Neuropathic pain
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 13 Apr 2016 Phase-I development for Back pain is ongoing in USA
  • 14 Jan 2014 Phase-I clinical trials in Back pain in USA prior to January 2014 (PO)
  • 19 Sep 2011 PSN 357 (ATx09 002) licensed to Aestus Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top